Hybridon Begins Phase I Trial With Gem 132

1 September 1996

Hybridon has begun a Phase I trial in London, UK, with its antisense compound GEM 132, for the treatment of patients with systemic human cytomegalovirus infection and retinitis.

The trial, the first of Hybridon's two-pronged development program, has enrolled 18 healthy volunteers and aims to study the safety and pharmacokinetics of the drug. The patients will receive doses of GEM 132 ranging between 0.125mg per kg and 0.5 mg per kg, to be administered intravenously.

The molecule is a hybridization composed of a strand of synthetic DNA with a protective cap of modified RNA at each end, and is thought to be the first advanced antisense compound to be administered to humans, say the company. It is designed to protect the drug from enzymatic activity and degradation in the body, the consequences of this being that its metabolic stability is greatly increased, and the need for frequent dosing is reduced.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight